Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Professional, scientific, and technical services entities : Prometheus biosciences inc save search
Nanomaterials in Personalized Medicine Global Markets Report 2023-2028 with Profiles and Potential of Major Players - BMS, Camurus, Cytimmune Sciences, Eisai, Gilead Sciences, and Ipsen Pharma
Published: 2023-11-16 (Crawled : 00:00) - prnewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
pharma report global potential
Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics
Published: 2023-10-13 (Crawled : 16:00) - prnewswire.com
ALPMF | News | $9.75 43.47% 200
|
Health Technology
|
| O: -1.86%
H: 0.0%
C: 0.0%
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: -2.78%
H: 0.04%
C: -0.57%
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: -0.21%
H: 0.42%
C: -1.17%
NVS | News | $97.28 2.27% 0.31% 3.7M
|
Health Technology
|
| O: -0.55%
H: 0.69%
C: -0.09%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
AZN | News | $70.85 1.03% 1.02% 5.6M
|
Health Technology
|
| O: -0.59%
H: 0.62%
C: -0.56%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.93%
H: 0.26%
C: -1.25%
management growing
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Published: 2023-04-16 (Crawled : 12:20) - globenewswire.com
MRK | $126.88 -0.05% -0.13% 7.5M
|
Health Technology
| Email alert
Add to watchlist
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
merck pipeline acquisition immunology
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
Published: 2023-03-09 (Crawled : 14:00) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: -2.72%
H: 0.45%
C: -2.87%
conference
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
Published: 2023-02-28 (Crawled : 21:00) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
financial results
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
Published: 2023-02-09 (Crawled : 22:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: -0.92%
H: 0.0%
C: 0.0%
biopharma global conference
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-03 (Crawled : 14:20) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
conference
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
Published: 2022-12-09 (Crawled : 01:00) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 8.72%
H: 0.0%
C: 0.0%
offering
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
Published: 2022-12-07 (Crawled : 12:20) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 181.13%
H: 0.0%
C: 0.0%
pra023 enabling positive phase 2b
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Published: 2022-11-09 (Crawled : 23:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 7.34%
C: 5.68%
financial results
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
Published: 2022-10-03 (Crawled : 13:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 3.76%
H: 1.23%
C: -1.77%
pra052 fda clearance application
Prometheus Biosciences to Participate at September Healthcare Conferences
Published: 2022-08-31 (Crawled : 21:00) - biospace.com/
MS | News 0 d | $93.76 1.81% 0.12% 6.4M
|
Finance
|
| O: 0.21%
H: 1.57%
C: 0.72%
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
Published: 2022-07-18 (Crawled : 00:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 3.49%
H: 0.0%
C: 0.0%
day
Prometheus Biosciences Completes Enrollment of the ARTEMIS-UC Cohort 1 Phase 2 Study in Ulcerative Colitis
Published: 2022-07-18 (Crawled : 14:20) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 3.49%
H: 0.0%
C: 0.0%
study phase 2 ulcerative colitis
Prometheus Biosciences Provides Enrollment Update in APOLLO-CD and ARTEMIS-UC Global Phase 2 Studies
Published: 2022-06-08 (Crawled : 12:20) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 3.73%
H: 3.2%
C: 1.86%
phase 2
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
Published: 2022-05-26 (Crawled : 19:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 1.21%
H: 1.51%
C: -0.53%
conference
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Published: 2022-03-30 (Crawled : 13:20) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 0.34%
H: 1.67%
C: -3.47%
pra023 disease phase 2
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Corporate Progress
Published: 2022-03-09 (Crawled : 22:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 2.08%
H: 9.62%
C: 8.89%
financial results report bioscience results
Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference
Published: 2022-03-01 (Crawled : 13:30) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 1.05%
H: 6.13%
C: -0.39%
health thc conference bioscience
Prometheus Biosciences Provides Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
Published: 2022-01-12 (Crawled : 14:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 0.51%
H: 9.28%
C: -10.28%
bioscience
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.